SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-14-301702
Filing Date
2014-08-08
Accepted
2014-08-08 07:01:03
Documents
10
Period of Report
2014-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d736209d10q.htm 10-Q 670036
2 EX-31.1 d736209dex311.htm EX-31.1 9072
3 EX-31.2 d736209dex312.htm EX-31.2 9097
4 EX-32.1 d736209dex321.htm EX-32.1 5324
  Complete submission text file 0001193125-14-301702.txt   6052855

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vnda-20140630.xml EX-101.INS 788335
6 XBRL TAXONOMY EXTENSION SCHEMA vnda-20140630.xsd EX-101.SCH 60140
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20140630_cal.xml EX-101.CAL 83445
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20140630_def.xml EX-101.DEF 391796
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20140630_lab.xml EX-101.LAB 424866
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20140630_pre.xml EX-101.PRE 468006
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 141025584
SIC: 2834 Pharmaceutical Preparations